Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Iniezione transendocardica di MSC allogeniche in pazienti con cardiomiopatia dilatativa non ischemica (DCMII)

28 settembre 2026 aggiornato da: Joshua M Hare

Uno studio di fase IIB randomizzato, controllato con placebo, multicentrico sull'efficacia comparativa e la sicurezza dell'iniezione transendocardica di MSC allogeniche rispetto al placebo in pazienti con cardiomiopatia dilatativa non ischemica

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

107

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Stanford, California, Stati Uniti, 94304
        • Stanford University
    • Florida
      • Miami, Florida, Stati Uniti, 33136
        • University of Miami Miller School of Medicine
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • University of Louisville
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Texas Heart Institute

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Men and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.
  2. Diagnosis of NIDCM with left ventricular ejection fraction ≤45%.
  3. Appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.
  4. Be a candidate for cardiac catheterization*
  5. Be willing to undergo DNA test.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy

  2. Clinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization

  3. Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries

  4. Valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent*

  5. Aortic stenosis with valve area ≤ 1.5cm2*

  6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction*, or Hypertrophic* cardiomyopathy

  7. Cardiomyopathy due to known toxin (e.g amyloid) Note: anthracycline induced cardiomyopathy will be allowed

  8. QTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)

  9. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent

  10. Have an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff

  11. A hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul

  12. Have liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN

  13. Have a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions

  14. Be a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.

  15. Have a history of organ or cell transplant rejection

  16. Have a clinical history of malignancy within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma

  17. Drug and/or alcohol abuse or dependence within the past 9 months

  18. Be serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C

  19. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to "Guidance to the PI" section with regards to LV thrombus, below)*

  20. Blood glucose levels (HbA1c) >10%

  21. Severe radiographic contrast allergy

  22. Known history of anaphylactic reaction to penicillin or streptomycin

  23. Hypersensitivity to dimethyl sulfoxide (DMSO)

  24. Non-cardiac condition with life expectancy < 1 year

  25. Acute stroke or transient ischemic attack within 3 months of enrollment

  26. Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods

  27. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)

  28. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted < 6 weeks prior to consent
    • non-transvenous epicardial or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
  29. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent

  30. Other MRI contraindications (e.g. subject body habitus incompatible with MRI)

  31. Need for advanced heart failure therapy (e.g. IV inotropes)

  32. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial

  33. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up

(*) Applies to subjects receiving product via transendocardial administration only

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Genotype A administered with placebo Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Sperimentale: Genotype A administered with hMSC Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Comparatore placebo: Genotype B administered with placebo Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Sperimentale: Genotype B administered with hMSC Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Comparatore placebo: Genotype C administered with placebo Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Sperimentale: Genotype C administered with hMSC Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in LVEF
Lasso di tempo: Baseline, 12 months

Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)

Baseline, 12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in global ventricular strain
Lasso di tempo: Baseline, 12 months

Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI

Baseline, 12 months
Change in left regional strain
Lasso di tempo: Baseline, 12 months

Change in regional ventricular strain as assessed via cardiac HARP MRI

Baseline, 12 months
Left ventricular function concordance
Lasso di tempo: 12 months

The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)

12 months
Change in LVEDVI
Lasso di tempo: Baseline, 12 months

Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI

Baseline, 12 months
Change in LVESVI
Lasso di tempo: Baseline, 12 months

Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI

Baseline, 12 months
Change in Maximal oxygen consumption (peak VO2)
Lasso di tempo: Baseline, 12 months

Change in maximal oxygen consumption (peak VO2) as assessed via treadmill

Baseline, 12 months
Change in Exercise tolerance
Lasso di tempo: Baseline, 12 months

Change in exercise tolerance as assessed as the distance covered via the six-minute walk test

Baseline, 12 months
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score
Lasso di tempo: Baseline, 12 months

Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.

Baseline, 12 months
Change in New York Heart Association (NYHA) Class
Lasso di tempo: Baseline, 12 months

NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)

Baseline, 12 months
Percent change in flow mediated diameter
Lasso di tempo: Baseline, 12 months

Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).

Baseline, 12 months
Change in EPC-CFU
Lasso di tempo: Baseline, 12 months

Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

Baseline, 12 months
Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
Lasso di tempo: Baseline, 12 months

Change in NT-proBNP as assessed via blood draw

Baseline, 12 months
Incidence of MACE
Lasso di tempo: 12 months

Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician

12 months
Incidence of TE-SAEs
Lasso di tempo: Day 30

Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician

Day 30

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Joshua Hare, MD, University of Miami

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 maggio 2021

Completamento primario (Stimato)

1 aprile 2027

Completamento dello studio (Stimato)

1 aprile 2027

Date di iscrizione allo studio

Primo inviato

15 luglio 2020

Primo inviato che soddisfa i criteri di controllo qualità

15 luglio 2020

Primo Inserito (Effettivo)

20 luglio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 20200566
  • CDMRP-PR191597 (Altro numero di sovvenzione/finanziamento: US Department of Defense)
  • 20-02-134 (Altro identificatore: BRANY IRB)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .